Skip to main content
IsoRay secures clearance for GammaTile, announces $8.25M offering

IsoRay's device for treating recurrent brain tumors, GammaTile therapy, has been granted 510(k) clearance by the FDA. The company has also announced a direct offering of shares of its stock in hopes of raising $8.25 million to be used as working capital, as well as for marketing purposes.

Full Story: